FDA officials said that the draft guidance is meant to address recommendations from two reports on the agency's response to COVID-19.
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback